Drugs / QHRD106
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06380699 | Mar → Nov 2023 | ischemic stroke | Changzhou Qianhong Bio-pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06388772 | Jul 2021 → Jul 2022 | ischemic stroke | Changzhou Qianhong Bio-pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07396337 | Jan → Oct 2026 expected | ischemic stroke | Changzhou Qianhong Bio-pharma Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QHRD106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06380699 ↗ |
| Route | Intramuscular | “Subjects will receive QHRD106 by intramuscular-injection (im).” NCT06380699 ↗ |